{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:59:09Z","timestamp":1789239549048,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10620-025-09464-3","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:17:27Z","timestamp":1760440647000},"page":"852-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1007","volume":"71","author":[{"given":"Wenjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaidong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"9464_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.973366","volume":"13","author":"Y Fu","year":"2022","unstructured":"Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, Zhang K, Li W, Chen W, Zhao S, Li Y, Ye W. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol. 2022;13:973366. https:\/\/doi.org\/10.3389\/fphar.2022.973366.","journal-title":"Front Pharmacol."},{"key":"9464_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u2013238. https:\/\/doi.org\/10.1038\/s41575-020-00381-6.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9464_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330595","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"9464_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. The Lancet 2021;397:2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"The Lancet"},{"key":"9464_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu Y-C, Lee T-Y, Ren W, Qin C, Jun DW, Toyoda H, Wong VW-S, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u2013398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9464_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/apt.16575","volume":"54","author":"SA Polyzos","year":"2021","unstructured":"Polyzos SA, Kechagias S, Tsochatzis EA. Review article: Non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. 2021;54:1013\u20131025. https:\/\/doi.org\/10.1111\/apt.16575.","journal-title":"Aliment Pharmacol Ther."},{"key":"9464_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778\u2013788. https:\/\/doi.org\/10.1136\/gutjnl-2021-324191.","journal-title":"Gut"},{"key":"9464_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cells14060428","volume":"14","author":"T Nakamura","year":"2025","unstructured":"Nakamura T, Masuda A, Nakano D, Amano K, Sano T, Nakano M, Kawaguchi T. Pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma. Cells 2025;14:428. https:\/\/doi.org\/10.3390\/cells14060428.","journal-title":"Cells"},{"key":"9464_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24:171\u2013189. https:\/\/doi.org\/10.1038\/s41573-024-01084-2.","journal-title":"Nat Rev Drug Discov."},{"key":"9464_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, Loomba R. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primer. 2025;11:14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primer."},{"key":"9464_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.clnesp.2023.10.001","volume":"58","author":"M Mokhtare","year":"2023","unstructured":"Mokhtare M, Abdi A, Sadeghian AM, Sotoudeheian M, Namazi A, Khalighi Sikaroudi M. Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the mediterranean diet. Clin Nutr ESPEN. 2023;58:221\u2013227. https:\/\/doi.org\/10.1016\/j.clnesp.2023.10.001.","journal-title":"Clin Nutr ESPEN."},{"key":"9464_CR12","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/liv.15947","volume":"44","author":"DJ Cuthbertson","year":"2024","unstructured":"Cuthbertson DJ, Keating SE, Pugh CJA, Owen PJ, Kemp GJ, Umpleby M, Geyer NG, Chinchilli VM, Stine JG. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver Int. 2024;44:2368\u20132381. https:\/\/doi.org\/10.1111\/liv.15947.","journal-title":"Liver Int."},{"key":"9464_CR13","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/hep4.2069","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol. Commun. 2022;6:3073\u20133082. https:\/\/doi.org\/10.1002\/hep4.2069.","journal-title":"Hepatol. Commun."},{"key":"9464_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:812\u2013821. https:\/\/doi.org\/10.1111\/dom.13584.","journal-title":"Diabetes Obes Metab."},{"key":"9464_CR15","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.3748\/wjg.v28.i26.3243","volume":"28","author":"F Bellanti","year":"2022","unstructured":"Bellanti F, Buglio AL, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol. 2022;28:3243\u20133257. https:\/\/doi.org\/10.3748\/wjg.v28.i26.3243.","journal-title":"World J Gastroenterol."},{"key":"9464_CR16","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, Tanaka T, Goto H, Nakano Y, Iida N, Arai K, Yamashita T, Mizukoshi E, Nakamura H, Kaneko S, Takamura T. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 2022;45:2064\u20132075. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Diabetes Care"},{"key":"9464_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2337\/dc21-1953","volume":"45","author":"R Pradhan","year":"2022","unstructured":"Pradhan R, Yin H, Yu O, Azoulay L. Glucagon-like peptide 1 receptor agonists and sodium\u2013glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care 2022;45:819\u2013829. https:\/\/doi.org\/10.2337\/dc21-1953.","journal-title":"Diabetes Care"},{"key":"9464_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70003","volume":"55","author":"LAM Konings","year":"2025","unstructured":"Konings LAM, Miguela\u00f1ez-Matute L, Boeren AMP, Van De Luitgaarden IAT, Dirksmeier F, De Knegt RJ, Tushuizen ME, Grobbee DE, Holleboom AG, Cabezas MC. Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a systematic review. Eur J Clin Invest. 2025;55:e70003. https:\/\/doi.org\/10.1111\/eci.70003.","journal-title":"Eur J Clin Invest."},{"key":"9464_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019;92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014.","journal-title":"Metabolism"},{"key":"9464_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","journal-title":"Metabolism"},{"key":"9464_CR21","doi-asserted-by":"publisher","unstructured":"R. Xu, D. Lian, Y. Xie, Z. Chen, Y. Wang, L. Mu, Y. Wang, B. Zhang, SGLT-2 inhibitors for non-alcoholic fatty liver disease: A review, Front. Biosci.-Landmark 28 (2023) 134. https:\/\/doi.org\/10.31083\/j.fbl2807134.","DOI":"10.31083\/j.fbl2807134"},{"key":"9464_CR22","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1194\/jlr.R066514","volume":"57","author":"ME Ertunc","year":"2016","unstructured":"Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57:2099\u20132114. https:\/\/doi.org\/10.1194\/jlr.R066514.","journal-title":"J Lipid Res."},{"key":"9464_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrm2391","volume":"9","author":"A Guilherme","year":"2008","unstructured":"Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367\u2013377. https:\/\/doi.org\/10.1038\/nrm2391.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"9464_CR24","doi-asserted-by":"publisher","first-page":"595371","DOI":"10.3389\/fmed.2021.595371","volume":"8","author":"AP Delli Bovi","year":"2021","unstructured":"Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med. 2021;8:595371. https:\/\/doi.org\/10.3389\/fmed.2021.595371.","journal-title":"Front Med."},{"key":"9464_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","volume":"30","author":"AL Gomes","year":"2016","unstructured":"Gomes AL, Teijeiro A, Bur\u00e9n S, Tummala KS, Yilmaz M, Waisman A, Theurillat J-P, Perna C, Djouder N. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 2016;30:161\u2013175. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.020.","journal-title":"Cancer Cell"},{"key":"9464_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","volume":"70","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang X, Li H. The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology 2019;70:1026\u20131037. https:\/\/doi.org\/10.1002\/hep.30506.","journal-title":"Hepatology"},{"key":"9464_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang J, Yu C-H, Li X-J, Yao J-M, Fang Z-Y, Yoon S-H, Yu W-Y. Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018. https:\/\/doi.org\/10.3389\/fcimb.2022.997018.","journal-title":"Front Cell Infect Microbiol."},{"key":"9464_CR28","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020;21:5214. https:\/\/doi.org\/10.3390\/ijms21155214.","journal-title":"Int J Mol Sci."},{"key":"9464_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat C-H, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 2018;155:629\u2013647. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.083.","journal-title":"Gastroenterology"},{"key":"9464_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515\u2013531. https:\/\/doi.org\/10.1210\/er.2010-0029.","journal-title":"Endocr Rev."},{"key":"9464_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5\u201314. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01511.x.","journal-title":"Diabetes Obes Metab."},{"key":"9464_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fphar.2014.00274","volume":"5","author":"Y Lu","year":"2014","unstructured":"Lu Y, Griffen SC, Boulton DW, Leil TA. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Front Pharmacol. 2014;5:274. https:\/\/doi.org\/10.3389\/fphar.2014.00274.","journal-title":"Front Pharmacol."},{"key":"9464_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102:248\u2013260. https:\/\/doi.org\/10.1016\/j.kint.2022.05.012.","journal-title":"Kidney Int."},{"key":"9464_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/dom.13980","volume":"22","author":"Y Matsubayashi","year":"2020","unstructured":"Matsubayashi Y, Yoshida A, Suganami H, Osawa T, Furukawa K, Suzuki H, Fujihara K, Tanaka S, Kaku K, Sone H. Association of increased hepatic insulin clearance and change in serum triglycerides or \u03b2-hydroxybutyrate concentration via the sodium\/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes Obes Metab. 2020;22:947\u2013956. https:\/\/doi.org\/10.1111\/dom.13980.","journal-title":"Diabetes Obes Metab."},{"key":"9464_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/hepr.13304","volume":"49","author":"N Akuta","year":"2019","unstructured":"Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531\u2013539. https:\/\/doi.org\/10.1111\/hepr.13304.","journal-title":"Hepatol Res."},{"key":"9464_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3349\/ymj.2022.63.7.619","volume":"63","author":"Z Xu","year":"2022","unstructured":"Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D. Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy. Yonsei Med J. 2022;63:619. https:\/\/doi.org\/10.3349\/ymj.2022.63.7.619.","journal-title":"Yonsei Med J."},{"key":"9464_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fendo.2020.00111","volume":"11","author":"Q Lv","year":"2020","unstructured":"Lv Q, Le L, Xiang J, Jiang B, Chen S, Xiao P. Liver transcriptomic reveals novel pathways of empagliflozin associated with type 2 diabetic rats. Front Endocrinol. 2020;11:111. https:\/\/doi.org\/10.3389\/fendo.2020.00111.","journal-title":"Front Endocrinol."},{"key":"9464_CR38","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep4.2005","volume":"6","author":"N Akuta","year":"2022","unstructured":"Akuta N, Kawamura Y, Fujiyama S, Saito S, Muraishi N, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study. Hepatol Commun. 2022;6:2286\u20132297. https:\/\/doi.org\/10.1002\/hep4.2005.","journal-title":"Hepatol Commun."},{"key":"9464_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","volume":"80","author":"KS Cheung","year":"2024","unstructured":"Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, Ho YC, Tan JT, Chan EW, Seto WK, Yuen MF, Leung WK. Effects of empagliflozin on liver fat in patients with metabolic dysfunction\u2013associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology 2024;80:916\u2013927. https:\/\/doi.org\/10.1097\/HEP.0000000000000855.","journal-title":"Hepatology"},{"key":"9464_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s11739-025-03902-w","volume":"20","author":"MA Amin","year":"2025","unstructured":"Amin MA, Sadik NA, Saad HA, Fawzy M, Elsheimy HA. The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 diabetes mellitus and metabolic-associated steatotic liver disease. Int Emerg Med. 2025;20:1025\u20131033. https:\/\/doi.org\/10.1007\/s11739-025-03902-w.","journal-title":"Int Emerg Med."},{"key":"9464_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107492","volume":"94","author":"Z Meng","year":"2021","unstructured":"Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, Sun B, Chen L. The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway. Int Immunopharmacol. 2021;94:107492. https:\/\/doi.org\/10.1016\/j.intimp.2021.107492.","journal-title":"Int Immunopharmacol."},{"key":"9464_CR42","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","volume":"22","author":"N Nasiri-Ansari","year":"2021","unstructured":"Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, Chatzigeorgiou A, Kalotychou V, Randeva MS, Chatha K, Kontzoglou K, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-\/-) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021;22:818. https:\/\/doi.org\/10.3390\/ijms22020818.","journal-title":"Int J Mol Sci."},{"key":"9464_CR43","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","volume":"36","author":"W Liu","year":"2024","unstructured":"Liu W, You D, Lin J, Zou H, Zhang L, Luo S, Yuan Y, Wang Z, Qi J, Wang W, Ye X, Yang X, Deng Y, Teng F, Zheng X, Lin Y, Huang Z, Huang Y, Yang Z, Zhou X, Zhang Y, Chen R, Xu L, Li J, Yang W, Zhang H. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation. Cell Metab. 2024;36:2245-2261.e6. https:\/\/doi.org\/10.1016\/j.cmet.2024.08.005.","journal-title":"Cell Metab."},{"key":"9464_CR44","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","volume":"45","author":"X Lin","year":"2024","unstructured":"Lin X, Cui X, Yang J, Jiang Y, Wei T, Xia L, Liao X, Li F, Wang D, Li J, Wu Q, Yin D, Le Y, Yang K, Wei R, Hong T. SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. Acta Pharmacol Sin. 2024;45:2579\u20132597. https:\/\/doi.org\/10.1038\/s41401-024-01389-3.","journal-title":"Acta Pharmacol Sin."},{"key":"9464_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150620","volume":"735","author":"J Lee","year":"2024","unstructured":"Lee J, Hong S-W, Kim M-J, Lim Y-M, Moon SJ, Kwon H, Park SE, Rhee E-J, Lee W-Y. Sodium-glucose cotransporter 2 inhibitors ameliorate ER stress-induced pro-inflammatory cytokine expression by inhibiting CD36 in NAFLD progression in vitro. Biochem Biophys Res Commun. 2024;735:150620. https:\/\/doi.org\/10.1016\/j.bbrc.2024.150620.","journal-title":"Biochem Biophys Res Commun."},{"key":"9464_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70023","volume":"45","author":"HY Ng","year":"2025","unstructured":"Ng HY, Zhang L, Tan JT, Hui RWH, Yuen MF, Seto WK, Leung WK, Cheung KS. Gut microbiota predicts treatment response to empagliflozin among <span style=\"font-variant:Small-caps;\">MASLD<\/span> patients without diabetes mellitus. Liver Int. 2025;45:e70023. https:\/\/doi.org\/10.1111\/liv.70023.","journal-title":"Liver Int."},{"key":"9464_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116167","volume":"223","author":"Z Jin","year":"2024","unstructured":"Jin Z, Yin R, Yuan Y, Zheng C, Zhang P, Wang Y, Weng H. Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024;223:116167. https:\/\/doi.org\/10.1016\/j.bcp.2024.116167.","journal-title":"Biochem Pharmacol."},{"key":"9464_CR48","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/nu14173531","volume":"14","author":"S Hata","year":"2022","unstructured":"Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, Kitagawa N, Hashimoto Y, Majima S, Senmaru T, Okada H, Ushigome E, Nakanishi N, Takakuwa H, Sasano R, Hamaguchi M, Fukui M. Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db\/db mice. Nutrients 2022;14:3531. https:\/\/doi.org\/10.3390\/nu14173531.","journal-title":"Nutrients"},{"key":"9464_CR49","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2223","author":"SW Lee","year":"2025","unstructured":"Lee SW, Park H, Lee M, Lee H, Kang ES. Sodium-glucose cotransporter-2 inhibitor enhances hepatic gluconeogenesis and reduces lipid accumulation via AMPK-SIRT1 activation and autophagy induction. Endocrinol Metab. 2025. https:\/\/doi.org\/10.3803\/EnM.2024.2223.","journal-title":"Endocrinol Metab."},{"key":"9464_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155612","volume":"145","author":"HJ Chun","year":"2023","unstructured":"Chun HJ, Kim ER, Lee M, Choi DH, Kim SH, Shin E, Kim J-H, Cho JW, Han DH, Cha B-S, Lee Y. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis. Metabolism 2023;145:155612. https:\/\/doi.org\/10.1016\/j.metabol.2023.155612.","journal-title":"Metabolism"},{"key":"9464_CR51","doi-asserted-by":"publisher","first-page":"104342","DOI":"10.1016\/j.ebiom.2022.104342","volume":"86","author":"F Furuya","year":"2022","unstructured":"Furuya F, Fujita Y, Matsuo N, Minamino H, Oguri Y, Isomura N, Ikeda K, Takesue K, Li Y, Kondo A, Mano F, Inagaki N. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. eBioMedicine 2022;86:104342. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104342.","journal-title":"eBioMedicine"},{"key":"9464_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.635556","volume":"12","author":"Q Wei","year":"2021","unstructured":"Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Front Endocrinol. 2021;12:635556. https:\/\/doi.org\/10.3389\/fendo.2021.635556.","journal-title":"Front Endocrinol."},{"key":"9464_CR53","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","volume":"59","author":"T Kawaguchi","year":"2024","unstructured":"Kawaguchi T, Fujishima Y, Wakasugi D, Io F, Sato Y, Uchida S, Kitajima Y. Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in japan. J Gastroenterol. 2024;59:1120\u20131132. https:\/\/doi.org\/10.1007\/s00535-024-02158-z.","journal-title":"J Gastroenterol."},{"key":"9464_CR54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/dom.14616","volume":"24","author":"S Meyh\u00f6fer","year":"2022","unstructured":"Meyh\u00f6fer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyh\u00f6fer SM, Holl RW. Elevated liver enzymes and comorbidities in type 2 diabetes: a multicentre analysis of 51 645 patients from the diabetes prospective follow-up ( DPV) database. Diabetes Obes Metab. 2022;24:727\u2013732. https:\/\/doi.org\/10.1111\/dom.14616.","journal-title":"Diabetes Obes Metab."},{"key":"9464_CR55","doi-asserted-by":"publisher","unstructured":"Y. Suzuki, H. Kaneko, A. Okada, R. Ohno, I. Yokota, K. Fujiu, T. Jo, N. Takeda, H. Morita, K. Node, H. Yasunaga, I. Komuro, Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus, J. Endocrinol. Invest. 47 (2023) 1261\u20131270. https:\/\/doi.org\/10.1007\/s40618-023-02246-6.","DOI":"10.1007\/s40618-023-02246-6"},{"key":"9464_CR56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/dom.15399","volume":"26","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Asakawa K, Kosakai Y, Lee T, Rokuda M. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in japan: a real-world data analysis, Diabetes. Obes Metab. 2024;26:997\u20131007. https:\/\/doi.org\/10.1111\/dom.15399.","journal-title":"Obes Metab."},{"key":"9464_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6:120\u2013132. https:\/\/doi.org\/10.1002\/hep4.1696.","journal-title":"Hepatol Commun."},{"key":"9464_CR58","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.16198","volume":"27","author":"K Hirayama","year":"2025","unstructured":"Hirayama K, Koshizaka M, Ishibashi R, Shoji M, Horikoshi T, Sakurai K, Yokote K. PRIME-V Study Group, Effects of the <span style=\"font-variant:Small-caps;\">SGLT2<\/span> inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: sub-analysis of a randomized controlled study. Diabetes Metab. 2025;27:2059\u20132069. https:\/\/doi.org\/10.1111\/dom.16198.","journal-title":"Diabetes Metab."},{"key":"9464_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, Jia L, He J, Huang C, Wei X, Chen J, Chen X, Zhou J, Wu L, Zhang P, Zhu Y, Xia H, Wen G, Liu Y, Liu S, Zeng Y, Zhou L, Jia H, He H, Xue Y, Wu F, Zhang H. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"key":"9464_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155657","volume":"146","author":"Y Shen","year":"2023","unstructured":"Shen Y, Cheng L, Xu M, Wang W, Wan Z, Xiong H, Guo W, Cai M, Xu F. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism 2023;146:155657. https:\/\/doi.org\/10.1016\/j.metabol.2023.155657.","journal-title":"Metabolism"},{"key":"9464_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"184","author":"H Jang","year":"2024","unstructured":"Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S, Lee W, Kim W. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med. 2024;184:375. https:\/\/doi.org\/10.1001\/jamainternmed.2023.8029.","journal-title":"JAMA Intern Med."},{"key":"9464_CR62","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 2018;142:1712\u20131722. https:\/\/doi.org\/10.1002\/ijc.31193.","journal-title":"Int J Cancer"},{"key":"9464_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274519","volume":"17","author":"M Hendryx","year":"2022","unstructured":"Hendryx M, Dong Y, Ndeke JM, Luo J. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLOS ONE 2022;17:e0274519. https:\/\/doi.org\/10.1371\/journal.pone.0274519.","journal-title":"PLOS ONE"},{"key":"9464_CR64","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.dld.2023.09.023","volume":"56","author":"R Lombardi","year":"2024","unstructured":"Lombardi R, Mantovani A, Cespiati A, Francione P, Maffi G, Del Zanna E, Maffeis C, Colecchia A, Passigato N, Ferrarese A, Cusumanu CD, Villani R, Orsi E, Grancini V, Airaghi L, Bignamini D, Serviddio G, Targher G, Dongiovanni P, Fargion S, Fracanzani AL. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. Dig Liver Dis. 2024;56:551\u2013558. https:\/\/doi.org\/10.1016\/j.dld.2023.09.023.","journal-title":"Dig Liver Dis."},{"key":"9464_CR65","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.3390\/ijms20205237","volume":"20","author":"T Jojima","year":"2019","unstructured":"Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci. 2019;20:5237. https:\/\/doi.org\/10.3390\/ijms20205237.","journal-title":"Int J Mol Sci."},{"key":"9464_CR66","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y, Rhee H, Yu MH, Bae J, Lee Y, Lee B-W, Kang ES, Cha B-S. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med. 2025;23:266. https:\/\/doi.org\/10.1186\/s12916-025-04017-x.","journal-title":"BMC Med."},{"key":"9464_CR67","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","volume":"16","author":"J-Y Wu","year":"2025","unstructured":"Wu J-Y, Hsu W-H, Kuo C-C, Tsai Y-W, Liu T-H, Huang P-Y, Chuang M-H, Hung K-C, Yu T, Lai C-C. A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD. Nat Commun. 2025;16:7459. https:\/\/doi.org\/10.1038\/s41467-025-62891-8.","journal-title":"Nat Commun."},{"key":"9464_CR68","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/jdi.70066","volume":"16","author":"D Tsuriya","year":"2025","unstructured":"Tsuriya D, Kobayashi K, Takeshita K, Hashimoto T, Kimura M, Muta Y, Yokomizo H, Takashi Y, Tsukamoto S, Tamura K, Kanasaki K, Kawanami D, Toyoda M. Liver function effects of SGLT2 inhibitor and GLP -1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study). J Diabetes Invest. 2025;16:1243\u20131253. https:\/\/doi.org\/10.1111\/jdi.70066.","journal-title":"J Diabetes Invest."},{"key":"9464_CR69","doi-asserted-by":"publisher","first-page":"120070","DOI":"10.1016\/j.lfs.2021.120070","volume":"286","author":"AM Abdelhamid","year":"2021","unstructured":"Abdelhamid AM, Youssef ME, Abd El-Fattah EE, Gobba NA, Gaafar AGA, Girgis S, Shata A, Hafez A-M, El-Ahwany E, Amin NA, Shahien MA, Abd-Eldayem MA, Abou-Elrous M, Saber S. Blunting p38 MAPK\u03b1 and ERK1\/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-\u03baB inactivation in mice intoxicated with carbon tetrachloride. Life Sci. 2021;286:120070. https:\/\/doi.org\/10.1016\/j.lfs.2021.120070.","journal-title":"Life Sci."},{"key":"9464_CR70","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang C-E, Chopra VK, De Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde A-M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med."},{"key":"9464_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl J Med. 2019;380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N. Engl J Med."},{"key":"9464_CR72","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kr\u00f6ller-Sch\u00f6n S, Kashani F, Roohani S, Welschof P, Kopp M, G\u00f6dtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, M\u00fcnzel T, Daiber A. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u2013385. https:\/\/doi.org\/10.1016\/j.redox.2017.06.009.","journal-title":"Redox Biol."},{"key":"9464_CR73","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"9464_CR74","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761\u2013772. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol."},{"key":"9464_CR75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-019-0869-2","volume":"18","author":"S Carbone","year":"2019","unstructured":"Carbone S, Dixon DL. The CANVAS program: Implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18:64. https:\/\/doi.org\/10.1186\/s12933-019-0869-2.","journal-title":"Cardiovasc Diabetol."},{"key":"9464_CR76","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc21-2043","volume":"45","author":"RA Herring","year":"2022","unstructured":"Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, Jackson N, Mendis J, Middleton B, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes. Diabetes Care 2022;45:1408\u20131415. https:\/\/doi.org\/10.2337\/dc21-2043.","journal-title":"Diabetes Care"},{"key":"9464_CR77","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300\u20132302. https:\/\/doi.org\/10.1056\/NEJMc1701990.","journal-title":"N Engl J Med."},{"key":"9464_CR78","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887.","journal-title":"Circulation"},{"key":"9464_CR79","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med."},{"key":"9464_CR80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262\u2013274. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007.","journal-title":"Ann Intern Med."},{"key":"9464_CR81","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/biom15030324","volume":"15","author":"M Zisis","year":"2025","unstructured":"Zisis M, Chondrogianni ME, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, Kassi E. Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): the role of cardiometabolic drugs in MASLD treatment. Biomolecules 2025;15:324. https:\/\/doi.org\/10.3390\/biom15030324.","journal-title":"Biomolecules"},{"key":"9464_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism 2024;157:155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937.","journal-title":"Metabolism"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09464-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09464-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09464-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:10:47Z","timestamp":1773292247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09464-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9464"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09464-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}